MannKind Corporation Reports 2023 Second Quarter Financial Results
August 07, 2023 16:00 ET
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 20232Q 2023 Endocrine Business Unit net revenues...
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
August 01, 2023 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
July 31, 2023 16:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 second quarter financial results and year to date financial...
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
June 22, 2023 06:05 ET
|
MannKind
Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)Time-in-range during waking...
Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
June 11, 2023 08:05 ET
|
MannKind
DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides...
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
May 24, 2023 08:30 ET
|
MannKind
DANBURY, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for...
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
May 09, 2023 20:21 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the...
Mannkind Corporation Reports 2023 First Quarter Financial Results
May 09, 2023 16:00 ET
|
MannKind
1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million $167 million of...
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
May 02, 2023 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a...